Resonance Health reports preliminary liver fibrosis results and flags GLP-1 trial opportunity
RHT: $0.075 +1.35% · MC: $43M
Resonance Health says preliminary analysis of 50 biopsy-confirmed subjects found its investigational MRI software achieved an AUROC of 0.82 for significant fibrosis, in line with a published FibroScan comparison, and 93.5% specificity for advanced fibrosis. The company says the results point to a potential role in GLP-1 and obesity trials, but the findings are from a single site, have not been independently verified and may change as more data becomes available.

Comments